These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 20212999)

  • 1. Optimization of influenza vaccine delivery to high risk children and adolescents.
    Paediatr Child Health; 1999 Nov; 4(8):531-2. PubMed ID: 20212999
    [No Abstract]   [Full Text] [Related]  

  • 2. Effect of a text messaging intervention on influenza vaccination in an urban, low-income pediatric and adolescent population: a randomized controlled trial.
    Stockwell MS; Kharbanda EO; Martinez RA; Vargas CY; Vawdrey DK; Camargo S
    JAMA; 2012 Apr; 307(16):1702-8. PubMed ID: 22535855
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluating the most effective distribution strategies to assure administration of pandemic H1N1 influenza vaccine to New York State children and adolescents: evaluation using the New York State Immunization Information System.
    Bednarczyk RA; DuVall S; Meldrum MD; Flynn MK; Santilli LA; Easton DE; Sharma P; Blog DS; Zansky SM; McNutt LA; Birkhead GS
    J Public Health Manag Pract; 2013; 19(6):589-97. PubMed ID: 23299656
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety, immunogenicity, and lot-to-lot consistency of a quadrivalent inactivated influenza vaccine in children, adolescents, and adults: A randomized, controlled, phase III trial.
    Cadorna-Carlos JB; Nolan T; Borja-Tabora CF; Santos J; Montalban MC; de Looze FJ; Eizenberg P; Hall S; Dupuy M; Hutagalung Y; Pépin S; Saville M
    Vaccine; 2015 May; 33(21):2485-92. PubMed ID: 25843270
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and immunogenicity of unadjuvanted subvirion monovalent inactivated influenza H3N2 variant (H3N2v) vaccine in children and adolescents.
    Munoz FM; Anderson EJ; Bernstein DI; Harrison CJ; Pahud B; Anderson E; Creech CB; Berry AA; Kotloff KL; Walter EB; Atmar RL; Bellamy AR; Chang S; Keitel WA
    Vaccine; 2019 Aug; 37(36):5161-5170. PubMed ID: 31375440
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pandemic influenza A/H1N1 vaccine administered sequentially or simultaneously with seasonal influenza vaccine to HIV-infected children and adolescents.
    Esposito S; Tagliaferri L; Daleno C; Valzano A; Picciolli I; Tel F; Prunotto G; Serra D; Galeone C; Plebani A; Principi N
    Vaccine; 2011 Feb; 29(8):1677-82. PubMed ID: 21199699
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Randomized, Double-blind, Active-controlled Phase III Trial of a Cell Culture-derived Quadrivalent Inactivated Influenza Vaccine in Healthy South Korean Children and Adolescents 6 Months to 18 Years of Age.
    Eun BW; Lee TJ; Lee J; Kim KH; Kim DH; Jo DS; Shin SH; Kim H; Kim KH; Kim YK
    Pediatr Infect Dis J; 2019 Sep; 38(9):e209-e215. PubMed ID: 31335572
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the safety of live attenuated influenza vaccine (LAIV) in children and adolescents with asthma and high-risk conditions: a population-based prospective cohort study conducted in England with the Clinical Practice Research Datalink.
    Caspard H; Steffey A; Mallory RM; Ambrose CS
    BMJ Open; 2018 Dec; 8(12):e023118. PubMed ID: 30530581
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of influenza vaccination of children on infection rates in Hutterite communities: a randomized trial.
    Loeb M; Russell ML; Moss L; Fonseca K; Fox J; Earn DJ; Aoki F; Horsman G; Van Caeseele P; Chokani K; Vooght M; Babiuk L; Webby R; Walter SD
    JAMA; 2010 Mar; 303(10):943-50. PubMed ID: 20215608
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Live attenuated influenza vaccine, trivalent, is safe in healthy children 18 months to 4 years, 5 to 9 years, and 10 to 18 years of age in a community-based, nonrandomized, open-label trial.
    Piedra PA; Gaglani MJ; Riggs M; Herschler G; Fewlass C; Watts M; Kozinetz C; Hessel C; Glezen WP
    Pediatrics; 2005 Sep; 116(3):e397-407. PubMed ID: 16140685
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influenza virus vaccine live intranasal--MedImmune vaccines: CAIV-T, influenza vaccine live intranasal.
    Drugs R D; 2003; 4(5):312-9. PubMed ID: 12952502
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the efficacy and safety of live attenuated cold-adapted influenza vaccine, trivalent, with trivalent inactivated influenza virus vaccine in children and adolescents with asthma.
    Fleming DM; Crovari P; Wahn U; Klemola T; Schlesinger Y; Langussis A; Øymar K; Garcia ML; Krygier A; Costa H; Heininger U; Pregaldien JL; Cheng SM; Skinner J; Razmpour A; Saville M; Gruber WC; Forrest B;
    Pediatr Infect Dis J; 2006 Oct; 25(10):860-9. PubMed ID: 17006278
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recommendations for Prevention and Control of Influenza in Children, 2018-2019.
    COMMITTEE ON INFECTIOUS DISEASES
    Pediatrics; 2018 Oct; 142(4):. PubMed ID: 30177511
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety of cold-adapted live attenuated influenza vaccine in a large cohort of children and adolescents.
    Bergen R; Black S; Shinefield H; Lewis E; Ray P; Hansen J; Walker R; Hessel C; Cordova J; Mendelman PM
    Pediatr Infect Dis J; 2004 Feb; 23(2):138-44. PubMed ID: 14872180
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vaccine recommendations for children and youth for the 2015/2016 influenza season.
    Moore DL;
    Paediatr Child Health; 2015 Oct; 20(7):389-94. PubMed ID: 26526862
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DNA vaccine priming for seasonal influenza vaccine in children and adolescents 6 to 17 years of age: A phase 1 randomized clinical trial.
    Houser KV; Yamshchikov GV; Bellamy AR; May J; Enama ME; Sarwar U; Larkin B; Bailer RT; Koup R; Paskel M; Subbarao K; Anderson E; Bernstein DI; Creech B; Keyserling H; Spearman P; Wright PF; Graham BS; Ledgerwood JE;
    PLoS One; 2018; 13(11):e0206837. PubMed ID: 30388160
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of live attenuated influenza vaccine and inactivated influenza vaccine in children 2-17 years of age in 2013-2014 in the United States.
    Caspard H; Gaglani M; Clipper L; Belongia EA; McLean HQ; Griffin MR; Talbot HK; Poehling KA; Peters TR; Veney N; Ambrose CS
    Vaccine; 2016 Jan; 34(1):77-82. PubMed ID: 26589519
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pediatricians' attitudes about collaborations with other community vaccinators in the delivery of seasonal influenza vaccine.
    Kempe A; Wortley P; O'Leary S; Crane LA; Daley MF; Stokley S; Babbel C; Dong F; Beaty B; Seewald L; Suh C; Dickinson LM
    Acad Pediatr; 2012; 12(1):26-35. PubMed ID: 21900066
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of the 2012/13 trivalent live and inactivated influenza vaccines in children and adolescents in Saxony-Anhalt, Germany: a test-negative case-control study.
    Helmeke C; Gräfe L; Irmscher HM; Gottschalk C; Karagiannis I; Oppermann H
    PLoS One; 2015; 10(4):e0122910. PubMed ID: 25885063
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of Influenza Vaccination of Children on Infection Rate in Hutterite Communities: Follow-Up Study of a Randomized Trial.
    Wang B; Russell ML; Moss L; Fonseca K; Earn DJ; Aoki F; Horsman G; Caeseele PV; Chokani K; Vooght M; Babiuk L; Webby R; Walter SD; Loeb M
    PLoS One; 2016; 11(12):e0167281. PubMed ID: 27977707
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.